4//SEC Filing
Renger John 4
Accession 0000899243-22-034915
CIK 0001805387other
Filed
Nov 2, 8:00 PM ET
Accepted
Nov 3, 4:28 PM ET
Size
13.2 KB
Accession
0000899243-22-034915
Insider Transaction Report
Form 4
Renger John
Chief Scientific Officer
Transactions
- Sale
Common Stock
2022-11-01$30.00/sh−25,000$750,005→ 2,704 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-11-01−10,018→ 60,110 totalExercise: $3.50Exp: 2029-04-02→ Common Stock (10,018 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2022-11-01−14,982→ 104,951 totalExercise: $10.28Exp: 2029-04-02→ Common Stock (14,982 underlying) - Exercise/Conversion
Common Stock
2022-11-01$3.50/sh+10,018$35,063→ 12,722 total - Exercise/Conversion
Common Stock
2022-11-01$10.28/sh+14,982$154,015→ 27,704 total
Footnotes (3)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 - $30.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
Documents
Issuer
Cerevel Therapeutics Holdings, Inc.
CIK 0001805387
Entity typeother
Related Parties
1- filerCIK 0001830363
Filing Metadata
- Form type
- 4
- Filed
- Nov 2, 8:00 PM ET
- Accepted
- Nov 3, 4:28 PM ET
- Size
- 13.2 KB